Join us on March 17, 2023 at 7:00 PM Central for the POETYK PSO program at the Marriott Warehouse Arts District, Gravier A-D in New Orleans, LA. Learn more about SOTYKTUTM (deucravacitinib) from speaker Andrew Blauvelt, MD, MBA and President of Oregon Medical Research Center in Portland, OR. Dr. Blauvelt will present efficacy and safety data from the POETYK clinical trials and share details on the science behind SOTYKTUTM. For more info on our accomplished speaker, see the bio below.
Disclaimer: This program is independent and is not part of the official AAD Annual Meeting, as planned by its Scientific Assembly Committee. This program does not qualify for continuing medical education (CME) credit.
Andrew Blauvelt, MD, MBA
Dr. Blauvelt grew up in Michigan and received his undergraduate degree in electrical engineering at Purdue University and his medical degree at Michigan State University. He completed his dermatology training at the University of Miami and basic immunology research training at the National Institutes of Health (NIH). In 2010, he returned to the classroom and received a Healthcare M.B.A. from a joint program at Oregon Health & Science University (OHSU) and Portland State University. Dr. Blauvelt has had three major phases of his career. First, he was a tenured Senior Investigator at the NIH for eight years, where he became well known for his pioneering work on HIV and Langerhans cells as well as for his studies into how human herpes viruses cause Kaposi’s sarcoma and pityriasis rosea. In the second phase of his career, which lasted seven years, he became Professor of Dermatology at OHSU and Chief of Dermatology at the VA Medical Center in Portland, Oregon. There he began to study psoriasis in depth, and his lab contributed to our understanding of how IL-23 and Th17 cells are key components in psoriasis pathogenesis. While at OHSU, he also organized a multidisciplinary center for care of complicated psoriasis patients and began participating in pivotal psoriasis clinical trials.
Beginning in the fall of 2011, Dr. Blauvelt transitioned to independent clinical research, becoming President and Owner of the Oregon Medical Research Center. The transition was a perfect opportunity to bring together all of his prior clinical and laboratory research expertise in psoriasis, immunology, and infectious diseases. He has served as Principal Investigator on numerous trials with a major emphasis on psoriasis. His dedication to science and discovery has resulted in more than 300 published papers and many formal honors.